Investor Highlights

Pharmaxis 2018 Directors' Report and Annual Financial Statements

Pharmaxis 2018 Directors' Report and Annual Financial Statements

Read report – pdf

FDA Factory Approval and Relaunch of Aridol in US Market

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the company has received approval from the United States Food and Drug Administration (FDA) for its manufacturing facility to produce the asthma diagnostic product Aridol for the US market.

Read full media release - pdf

Presentation to Bioshares 2018 Conference

Presentation by Gary Phillips at 2018 Bioshares Conference - Creating and Maintaining Competitive Tension

View presentation – pdf

Capital Raising Presentation

Presentation for August 2018 Placement

View presentation – pdf

Pharmaxis Announces A$24m Placement


  • A$24.0m being raised in a two tranche placement to global sector specialist and institutional investors
  • A$54m pro-forma cash balance post raising. Strengthened balance sheet to assist with LOXL2 partnering negotiations expected in 2H18 Issue price of A$0.325 represents a 3.1% premium to last closing price
  • Arix Bioscience plc invests A$14.2m for a 11% holding in the Company
  • Existing shareholder BVF Partners LP invests A$7.1m to increase its holding to 22.9%
  • Arix Investment Director Edward Rayner to be nominated to join the Pharmaxis Board
Read full media release - pdf